Emil Kuriakose - 23 Jan 2023 Form 4 Insider Report for Calithera Biosciences, Inc.

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: N/A
Reported as of: 23 Jan 2023
Net transaction value: -$35.24
SEC form: 4
Accepted by SEC: 25 Jan 2023, 15:00:21 UTC
Prior SEC filing: 27 Jan 2022
Next SEC filing: 19 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Emil Kuriakose

Key filing fact

Emil Kuriakose filed Form 4 for Calithera Biosciences, Inc. on 25 Jan 2023.

Key facts

This page summarizes Emil Kuriakose's Form 4 filing for Calithera Biosciences, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 25 Jan 2023, 15:00.

Change

Previous filing in this sequence was filed on 27 Jan 2022.
Current net transaction value: -$35.24.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CALA transaction

Common Stock

Tax liability

Transaction value: $35.24
Shares: -79
Change %: -2.2%
Price: $0.4461
Shares after: 3,539
Date: 23 Jan 2023
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Footnote F2

The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 23, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Footnote F3

Includes 125 shares acquired on each of June 10, 2022 and December 9, 2022, under the Company's 2014 Employee Stock Purchase Plan.